Anti-phospholipase A2 receptor antibodies in primary membranous nephropathy—10 key points
Open Access
- 1 February 2018
- journal article
- editorial
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 33 (2) , 212-213
Abstract
Membranous nephropathy (MN) remains the most common primary cause of nephrotic syndrome in Europe and a common cause of end-stage renal failure. The reporting of anti-phospholipase A2 receptor antibody (PLA2RAb) positivity in 70% of patients with primary MN (PMN) in 2009 was a significant advance in the understanding of the disease pathogenicity.Keywords
This publication has 8 references indexed in Scilit:
- A Proposal for a Serology-Based Approach to Membranous NephropathyJournal of the American Society of Nephrology, 2016
- Membranous Nephropathy: A Journey From Bench to BedsideAmerican Journal of Kidney Diseases, 2016
- Epitope Spreading of Autoantibody Response to PLA2R Associates with Poor Prognosis in Membranous NephropathyJournal of the American Society of Nephrology, 2015
- Antiphospholipase A2 Receptor Antibody Levels Predict the Risk of Posttransplantation Recurrence of Membranous NephropathyTransplantation, 2015
- Diagnostic accuracy of PLA2R autoantibodies and glomerular staining for the differentiation of idiopathic and secondary membranous nephropathy: an updated meta-analysisScientific Reports, 2015
- Association of Anti-PLA2R Antibodies with Outcomes after Immunosuppressive Therapy in Idiopathic Membranous NephropathyClinical Journal of the American Society of Nephrology, 2014
- Phospholipase A2 Receptor Autoantibodies and Clinical Outcome in Patients with Primary Membranous NephropathyJournal of the American Society of Nephrology, 2014
- Anti-Phospholipase A2 Receptor Antibodies Correlate with Clinical Status in Idiopathic Membranous NephropathyClinical Journal of the American Society of Nephrology, 2011